Select All | None | words selected.

Top 50 Keywords:
3d
chain
molecule
molecular structure
model
crystal
chemical formula
chemical compound
structural
built structure
bond
atomic
skeletal
clinical trials
oral bioavailability
pharmacokinetics
efficacy
combination therapy
small molecule
oral administration
antineoplastic
aspergillosis
bms-207147
broad-spectrum
experimental
c22h17f2n5os
ergosterol
cell membrane
cryptococcus neoformans
dermatophytes
antifungal agent
er-30346
fungal infection
fosravuconazole
candidiasis
t-cell activation
anti-leishmanial
oncology drug
immune checkpoint inhibitor
immune tolerance
immuno-oncology drug
immunosuppressive metabolite
indole scaffold
kynurenine pathway
linrodostat
pharmacological research
tumor microenvironment
piperidinyl amide
pyridine derivative
research molecule

Other Keywords:
signal transduction
therapeutic potential
trifluoromethyl group
tryptophan metabolism inhibitor
long half-life
triazole antifungal
onychomycosis
quinolone antibiotics
gram-negative bacteria
gram-positive bacteria
medicinal chemistry
metabolic pathway
microbial susceptibility
pharmacodynamics
resistance mechanisms
fluoroquinolone antibiotic
respiratory infections
side effects
structural analog
synthetic compound
therapeutic application
therapeutic efficacy
topoisomerase iv inhibitor
garenoxacin
enzymatic inhibition
patient
antibacterial agent
prodrug
ravuconazole
research
sterol biosynthesis inhibitor
therapeutic
administration routes
adverse reactions
bacterial dna replication

drug interactions
bioavailability
bms-284756
broad-spectrum activity
c23h20f2n2o4
des-f(6) quinolone
dna gyrase inhibitor
dosage forms
ido1 inhibitor
selectivity
drug mechanism
clinical development
atpase inhibitor
bms-986435
bristol myers squibb
c19h21f2n3o3
cardiac myosin inhibitor
cardiology
contractility reduction
targeted therapy
delocamten
diastolic dysfunction
ejection fraction
hcm
heart failure
hypercontractility
hypertrophic cardiomyopathy
ubiquitin-proteasome
relapsed myeloma
left ventricular hypertrophy
hematologic malignancy
bms-986348
c32h30fn5o4
cc-92480
celmod agent

cereblon modulator
crbn binding
e3 ligase
ikaros degradation
refractory myeloma
ikzf1 degrader
ikzf3 degrader
immunomodulatory
mezigdomide
multiple myeloma
neutropenia
protein degrader
investigational drug
lvot gradient
cancer immunotherapy
reversible binding
jnj-70033093
milvexian
myocardial infarction
once daily
p-glycoprotein
postoperative venous thromboembolism
safety profile
factor xia inhibitor
aiolos degradation
serine protease
stroke prevention
thrombosis prevention
antineoplastic agent
bms-986205
c24h24clfn2o
intrinsic pathway
direct inhibitor
myk-224
target occupancy

myosin atpase
non-obstructive hcm
obstructive hcm
oral availability
phase 2 trial
preclinical study
sarcomere modulator
usan
cyp450
anticoagulant
antithrombotic agent
bleeding risk
bms-986177
bridging anticoagulation
c28h23cl2f2n9o2
coagulation cascade
urinary tract infections